Lantu Motors' first-quarter deliveries increased by approximately 30% year-on-year; Dongpeng Beverage plans to buy back up to 2 billion yuan of A-shares.

Caixin Media April 1 News (Edited by Feng Yi) Caixin Media brings you today’s key important announcements for Hong Kong stocks

1）Company Highlights

Saile Si (09927.HK): In the first three months, cumulative vehicle sales totaled 884,000 units, up 29.37% year over year. March sales were 275,000 units, up 11.68% year over year.

NIO-SW (09866.HK): In the first three months, deliveries totaled 355,000 vehicles, up 136.0% year over year.

Great Wall Motor (02333.HK): In the first three months, total vehicle sales were approximately 88.4k units, up 4.79% year over year; March sales were approximately 27.5k units, up 8.38% year over year.

Li Auto-W (02015.HK): In March, delivered 41,053 new vehicles, up 11.94% year over year.

Lantu Auto (07489.HK): In the first three months, delivered 33,892 new cars, up 30.2% year over year; in March, delivered 15,019 units, up 50.1% year over year, with a quarter-over-quarter increase of 79.7%.

Bay Area Development (00737.HK): In February, monthly total toll revenue for the Guangshen Expressway, the Guangzhu West Line Expressway, and the Jianghai Expressway (Shenzhen segment) was approximately RMB 139 million, RMB 35.5k, and RMB 269.1k, respectively, representing decreases of 33%, 20%, and 7%, year over year, respectively.

Shenzhen Expressway Co., Ltd. (00548.HK): In February, toll revenue for the Meiguan Expressway, the section of Jihuo East, the section of Jihuo West, the Jianghai project, and the Outer Ring project was RMB 106.2k, RMB 67.07M, RMB 45.73M, RMB 7.13M, and RMB 38.84M, respectively.

Haisco Pharmaceutical (02696.HK): Recently, the Phase 1 clinical trial application (INDs) for HLX319 (HLX319), the company’s self-developed biosimilar monoclonal antibody injection (subcutaneous injection) of pertuzumab, was approved by the National Medical Products Administration (NMPA). The company plans to carry out the related clinical trials in mainland China once the conditions are met in the near term.

Sihuan Pharmaceutical (00460.HK): Reached a strategic cooperation with BeiGene Scientific (02315.HK) to accelerate the development of innovative drugs across multiple areas, including weight reduction, through an AI-driven full-human antibody R&D platform.

China Antibody-B (03681): The Phase 2 clinical trial for SM17 in China for atopic dermatitis completed dosing of the first patient.

Chaoju Eye (02219.HK): Subsidiary subscribed for wealth management products issued by Bank of China with a total principal amount of RMB 260 million.

Hua Ying Construction (01582.HK): Won a contract for the Yuen Long public housing project, with a contract value of approximately HK$1.43 billion.

Datian Education (08417.HK): Completed the acquisition of all equity interests of Yanyi Education Co., Ltd.

Datang Environment (01272.HK): Plans to spend approximately RMB 24.5741 million to acquire scrapped wind power equipment.

2）Share Buyback Updates

Eastroc Beverage (09980.HK): Plans to allocate between RMB 1.0 billion and RMB 2.0 billion to repurchase A-share shares, with no less than 90% to be used for cancellation and reduction of registered capital.

Tencent Holdings (00700.HK): Spent HK$300 million to repurchase 603k shares, with a repurchase price of HK$493.2–504 per share.

AIA Group (01299.HK): Spent HK$201 million to repurchase 30.84M shares, with a repurchase price of HK$87.25–88.6 per share.

China Resources Gas (01193.HK): Spent HK$12.7448 million to repurchase 672.4k shares, with a repurchase price of HK$18.81–19.1 per share.

Pop Mart (09992.HK): Spent HK$99.44596 million to repurchase 670k shares.

A large volume of information and precise interpretation are available on the Sina Finance APP